Getting Ahead of Nonalcoholic Steatohepatitis (NASH)

To participate in this activity, please:

Log in Sign Up

Nonalcoholic fatty liver disease, more recently known as metabolic dysfunction-associated steatotic liver disease (MASLD), affects nearly 1 in 4 adults. Left untreated, patients with MASLD can suffer metabolic, cardiovascular, and liver-related complications including cirrhosis and death. Noninvasive tests are widely available to screen patients at risk of MASLD. Weight loss and cardiovascular risk reduction, followed by directed pharmacotherapy, are the mainstays of treatment.In this 1-hour journal-style review article, supplemented with video clips of key concepts, Drs. Jay Shubrook and Arun Sanyal provide their insights about the primary care identification, diagnosis, and treatment of patients with MASLD.

Course Credit:

1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
0.50 Pharmacology Hours

Dates:

Opens: 2024-01-26
Closes: 2025-02-01

Target Audience:

The primary target audience includes healthcare professionals who care for patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with a focus on primary care providers (MD, PA, and NP).

This program is supported by an educational grant provided by Novo Nordisk.

Accreditation Information

    Presenting Faculty

  • Arun J. Sanyal, MD

    Director,  Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
    Interim Chair, Division of Gastroenterology, Hepatology, and Nutrition
    Virginia Commonwealth University Medical Center
    Richmond, Virginia

  • Jay H. Shubrook, DO

    Director of Clinical Research and Diabetes Services
    TUCA/Solano County Family Health Services
    Professor, and Interim Chair
    Department of Clinical Sciences and Community Health
    Touro University California College of Osteopathic Medicine
    Vallejo, California